摘要
目的:观察米非司酮埋植剂抑制大鼠异位子宫内膜的效果。方法:分别在子宫内膜异位症模型大鼠皮下埋植单根0.75、1.5、3.0cm长和2根、3根、4根3cm长规格米非司酮埋植剂,3个月后测定并计算异位子宫内膜抑制率,并与不含药对照组进行比较。结果:1根3cm长埋植剂在前15d米非司酮释放速度约为9μg.d-1,30d后约为5μg.d-1,并可维持6个月以上。皮下植入1根1.5、3.0cm长或2根3.0cm长埋植剂1个月时,异位内膜抑制率分别为(18.6±17.3)%、(31.5±12.7)%、(72.2±12.3)%,与对照组比较具有显著性差异(P<0.05)。结论:米非司酮皮下埋植剂作为治疗子宫内膜异位症的长效制剂是可行的。
OBJECTIVE： To observe the efficacy of mifepristone - releasing implants for endometriosis in rats. METHODS： Mifepristone- releasing implants （one tube at 0.75, 1.5, and 3.0 cm in length, or 2, 3, 4 tubes at 3 cm in length） were embedded subcutaneously in model rats with endometriosis. The inhibition ratio on the endometriosis was measured 3 months later and compared with the placebo control group, RESULTS： In vitro mean drug release rate of about 9 μg . d^-1 was achieved for the one - tube implant at 3 cm in length for the first 15 days, but reduced to 5 μg. d^-1 after 30 days and which was maintained for over 6 months. Inhibition ratios of （18.6±17.3）%, （31.5± 12.7）% and （72.2± 12.3）% on the growth of endometrial explants were achieved after subcutaneous implantation of mifepristone - releasing implants （1 tube at 1,5 cm or 3 cm in length or 2 tubes at 3.0 cm in length）, showing significance differences as compared with control group （P〈0.05） . CONCLUSION： It is feasible for subcutaneous mifepristone- releasing implant as extended action drugs for endometriosis.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第4期264-265,共2页
China Pharmacy
基金
天津市自然科学基金资助项目(023803511)
